Literature DB >> 27077643

Preoperative Evaluation of Prostate Cancer Aggressiveness: Using ADC and ADC Ratio in Determining Gleason Score.

Sungmin Woo1, Sang Youn Kim1, Jeong Yeon Cho1,2, Seung Hyup Kim1,2.   

Abstract

OBJECTIVE: The objective of our study was to evaluate apparent diffusion coefficient (ADC) and various ADC ratios in determining aggressiveness of prostate cancer.
MATERIALS AND METHODS: One hundred sixty-five patients with biopsy-proven prostate cancer underwent 3-T MRI followed by radical prostatectomy. ADC and ADC ratios were calculated using the peripheral zone, transition zone, same zone as the tumor, and urinary bladder as references. ADC and ADC ratios were correlated with Gleason score using the Spearman correlation coefficient (ρ) and were compared between low-grade (Gleason score = 6) and high-grade (Gleason score ≥ 7) prostate cancer using the unpaired t test. ROC curves were used to compare diagnostic accuracies of ADC and ADC ratios in determining high-grade prostate cancer.
RESULTS: Fifty-six (33.9%) and 109 (66.1%) patients had low- and high-grade prostate cancer, respectively. ADC (ρ = -0.476) and all ADC ratios (ρ = -0.397, -0.412, -0.381, and -0.474, respectively) correlated significantly with Gleason score (p < 0.001) and were significantly lower in patients with high-grade prostate cancer (p < 0.001). For predicting high-grade prostate cancer, tumor ADC and tumor-to-urinary bladder ADC ratio showed the highest AUC (0.794 and 0.790, respectively) but without statistically significant difference (p = 0.803). AUC of tumor ADC (0.794) was statistically significantly higher than those of the tumor-to-peripheral zone and tumor-to-transition zone ADC ratios (0.746, p = 0.039; 0.751, p = 0.027; respectively). AUC of tumor ADC was not statistically significantly higher than that of the tumor-to-tumor zone ADC ratio (0.763, p = 0.193). AUC calculated using the tumor-to-urinary bladder ADC ratio was statistically significantly higher than that using the tumor-to-transition zone ADC ratio (p = 0.028) and marginally higher than that from tumor-to-peripheral zone ADC ratio (p = 0.080). Otherwise, no significant differences were seen in the AUCs (p = 0.193-0.828).
CONCLUSION: Both ADC and various ADC ratios correlated significantly with Gleason score and were significant predictors of high-grade prostate cancer. However, no benefit was found in using ADC ratio over ADC.

Entities:  

Keywords:  ADC ratio; Gleason score; apparent diffusion coefficient; prostate cancer; radical prostatectomy

Mesh:

Year:  2016        PMID: 27077643     DOI: 10.2214/AJR.15.15894

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  14 in total

1.  Utility of quantitative apparent diffusion coefficient measurements and normalized apparent diffusion coefficient ratios in the diagnosis of clinically significant peripheral zone prostate cancer.

Authors:  Tan B Nguyen; Alexander Ushinsky; Albert Yang; Michael Nguyentat; Sara Fardin; Edward Uchio; Chandana Lall; Thomas Lee; Roozbeh Houshyar
Journal:  Br J Radiol       Date:  2018-06-21       Impact factor: 3.039

2.  Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer.

Authors:  Elmira Hassanzadeh; Francesco Alessandrino; Olutayo I Olubiyi; Daniel I Glazer; Robert V Mulkern; Andriy Fedorov; Clare M Tempany; Fiona M Fennessy
Journal:  Abdom Radiol (NY)       Date:  2018-05

3.  Magnetic resonance fingerprinting in prostate cancer before and after contrast enhancement.

Authors:  Young Sub Lee; Moon Hyung Choi; Young Joon Lee; Dongyeob Han; Dong-Hyun Kim
Journal:  Br J Radiol       Date:  2021-08-20       Impact factor: 3.039

4.  Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?

Authors:  Ely R Felker; Steven S Raman; Daniel J Margolis; David S K Lu; Nicholas Shaheen; Shyam Natarajan; Devi Sharma; Jiaoti Huang; Fred Dorey; Leonard S Marks
Journal:  AJR Am J Roentgenol       Date:  2017-08-31       Impact factor: 3.959

5.  Targeted Biopsy Validation of Peripheral Zone Prostate Cancer Characterization With Magnetic Resonance Fingerprinting and Diffusion Mapping.

Authors:  Ananya Panda; Gregory OʼConnor; Wei Ching Lo; Yun Jiang; Seunghee Margevicius; Mark Schluchter; Lee E Ponsky; Vikas Gulani
Journal:  Invest Radiol       Date:  2019-08       Impact factor: 6.016

6.  Evaluation of Peripheral Zone Prostate Cancer Aggressiveness Using the Ratio of Diffusion Tensor Imaging Measures.

Authors:  Aslihan Onay; Gokhan Ertas; Metin Vural; Omer Acar; Yesim Saglican; Bilgen Coskun; Sergin Akpek
Journal:  Contrast Media Mol Imaging       Date:  2017-09-26       Impact factor: 3.161

Review 7.  The value of advanced MRI techniques in the assessment of cervical cancer: a review.

Authors:  Evelyn Dappa; Tania Elger; Annette Hasenburg; Christoph Düber; Marco J Battista; Andreas M Hötker
Journal:  Insights Imaging       Date:  2017-08-21

8.  The Apparent Diffusion Coefficient (ADC) is a useful biomarker in predicting metastatic colon cancer using the ADC-value of the primary tumor.

Authors:  Elias Nerad; Andrea Delli Pizzi; Doenja M J Lambregts; Monique Maas; Sharan Wadhwani; Frans C H Bakers; Harrie C M van den Bosch; Regina G H Beets-Tan; Max J Lahaye
Journal:  PLoS One       Date:  2019-02-05       Impact factor: 3.240

9.  A Pilot Study of Multidimensional Diffusion MRI for Assessment of Tissue Heterogeneity in Prostate Cancer.

Authors:  Björn J Langbein; Filip Szczepankiewicz; Carl-Fredrik Westin; Camden Bay; Stephan E Maier; Adam S Kibel; Clare M Tempany; Fiona M Fennessy
Journal:  Invest Radiol       Date:  2021-12-01       Impact factor: 6.016

10.  Discrimination between clinical significant and insignificant prostate cancer with apparent diffusion coefficient - a systematic review and meta analysis.

Authors:  Hans-Jonas Meyer; Andreas Wienke; Alexey Surov
Journal:  BMC Cancer       Date:  2020-05-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.